Citigroup’s Alterity Therapeutics ATHE Stock Holding History

Citigroup’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Buy	+1	New	+$4	﹤0.01%	5618
2026 Q1	–	Sell	-1	Closed	-$3	–	5942
2025 Q4	$3	Sell	1 -635	-100%	-$2.43K	﹤0.01%	5895
2025 Q3	$2.4K	Buy	+636	New	+$3.07K	﹤0.01%	5438
2016 Q1	–	Sell	-3	Closed	–	–	7443
2015 Q4	$0	Buy	+3	New	+$153	﹤0.01%	7536
2015 Q3	–	Sell	-12	Closed	-$1K	–	7362
2015 Q2	$1K	Buy	+12	New	+$901	﹤0.01%	7266
2015 Q1	–	Sell	-1	Closed	–	–	7190
2014 Q4	$0	Sell	1 -28	-97%	-$3.03K	﹤0.01%	7101
2014 Q3	$4K	Sell	29 -10	-26%	-$1.34K	﹤0.01%	6625
2014 Q2	$5K	Buy	39 +14	+56%	+$1.6K	﹤0.01%	6444
2014 Q1	$4K	Sell	25 -25	-50%	-$13.8K	﹤0.01%	6635
2013 Q4	$21K	Buy	+50	New	+$15K	﹤0.01%	6147

Other funds holding ATHE

TLCM

Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citigroup's ATHE Position: Q2 2026 in Review

Citigroup opened a new position in Alterity Therapeutics (ATHE) in Q2 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #5618 among its holdings. This is a return to the name: Citigroup previously reported a position in ATHE as recently as Q4 2025.

Citigroup first reported a position in ATHE in Q4 2013 and has held it in 10 quarters since. The position peaked at $21K in Q4 2013. 22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

Citigroup held 1 share of Alterity Therapeutics worth $5 as of Q2 2026.
Alterity Therapeutics was a new Citigroup position in Q2 2026.
Alterity Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5618 holding.
Citigroup first reported a position in Alterity Therapeutics in Q4 2013 and has held it in 10 quarters since.
Citigroup's Alterity Therapeutics position peaked at $21K in Q4 2013.
22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.